Show simple item record

dc.contributor.authorPerez-Lopez, R
dc.contributor.authorTunariu, N
dc.contributor.authorPadhani, AR
dc.contributor.authorOyen, WJG
dc.contributor.authorFanti, S
dc.contributor.authorVargas, HA
dc.contributor.authorOmlin, A
dc.contributor.authorMorris, MJ
dc.contributor.authorde Bono, J
dc.contributor.authorKoh, D-M
dc.date.accessioned2019-07-22T14:59:24Z
dc.date.issued2019-08
dc.identifier.citationRadiology, 2019, 292 (2), pp. 273 - 286
dc.identifier.issn0033-8419
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3303
dc.identifier.eissn1527-1315
dc.identifier.doi10.1148/radiol.2019181931
dc.description.abstractThe management of advanced prostate cancer has changed substantially with the availability of multiple effective novel treatments, which has led to improved disease survival. In the era of personalized cancer treatments, more precise imaging may help physicians deliver better care. More accurate local staging and earlier detection of metastatic disease, accurate identification of oligometastatic disease, and optimal assessment of treatment response are areas where modern imaging is rapidly evolving and expanding. Next-generation imaging modalities, including whole-body MRI and molecular imaging with combined PET and CT and combined PET and MRI using novel radiopharmaceuticals, create new opportunities for imaging to support and refine management pathways in patients with advanced prostate cancer. This article demonstrates the potential and challenges of applying next-generation imaging to deliver the clinical promise of treatment breakthroughs.
dc.formatPrint-Electronic
dc.format.extent273 - 286
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectProstate
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectPositron-Emission Tomography
dc.subjectMagnetic Resonance Imaging
dc.subjectNeoplasm Staging
dc.subjectFollow-Up Studies
dc.subjectMale
dc.subjectMultimodal Imaging
dc.subjectPositron Emission Tomography Computed Tomography
dc.titleImaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art.
dc.typeJournal Article
rioxxterms.versionofrecord10.1148/radiol.2019181931
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2019-08
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfRadiology
pubs.issue2
pubs.notes6 months
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Molecular Imaging
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume292
pubs.embargo.terms6 months
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
icr.researchteamTranslational Molecular Imagingen_US
dc.contributor.icrauthorKoh, Dow-Muen
dc.contributor.icrauthorDe Bono, Johannen
dc.contributor.icrauthorOyen, Willemen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record